Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2022 Aug;20(8):1830-1838.
doi: 10.1111/jth.15748. Epub 2022 May 23.

Platelet transfusion and anticoagulation in hematological cancer-associated thrombosis and thrombocytopenia: The CAVEaT multicenter prospective cohort

Stephen Booth  1 ; HaemSTAR Network  2 ; Michael Desborough  3 , Nicola Curry  3 , Simon Stanworth  4   5
Collaborators, Affiliations
Free article
Multicenter Study

Platelet transfusion and anticoagulation in hematological cancer-associated thrombosis and thrombocytopenia: The CAVEaT multicenter prospective cohort

Stephen Booth et al. J Thromb Haemost. 2022 Aug.
Free article

Abstract

Background: Venous thromboembolism (VTE) in patients with thrombocytopenia represents a complex management challenge.

Objectives: To describe practice, document outcomes, and compare management to national guidelines.

Methods: We present a prospective multicenter cohort of 105 patients with hematological cancer, VTE within 28 days, and platelets <50 × 109 /L from May 14, 2019 to April 24, 2021 from 20 sites.

Results: Median age was 64 and median initial platelet count 28 × 109 /L. Thromboses were: 46% catheter-associated, 11% lower limb, 33% pulmonary emboli (PE), and 10% other sites. Management was according to International Society on Thrombosis and Haemostasis (ISTH) guidance in 30 (47%) of 64 patients with high-risk thrombosis and 2 (5%) of low-risk thrombosis (catheter-associated or asymptomatic subsegmental PE). Twelve patients (11%) received no anticoagulation. At 28 days mortality was 15%, 8% experienced VTE progression, 7% experienced major bleeding, and 25% experienced clinically relevant non-major bleeding. Four inferior vena cava filters were placed, two were later removed. The median number of platelet units transfused was 5 (range 0-53). Twenty-seven percent of patients had a change of management strategy by 28 days. There was no clear relationship among platelet transfusion threshold, anticoagulant dose reduction threshold, and risk of thrombosis progression or major bleeding.

Conclusions: This data set demonstrates the heterogeneity of approaches used in patients presenting with severe thrombocytopenia and acute thrombosis and confirms the high rates of bleeding in this cohort with thrombosis progression rates similar to the wider cancer-associated thrombosis population. Randomized data is required to inform the optimal management.

Keywords: anticoagulants; hematologic neoplasms; platelet transfusion; thrombocytopenia; thrombosis.

PubMed Disclaimer

References

REFERENCES

    1. Kopolovic I, Conter HJ, Kuo KHM. Management of cancer-associated venous thromboembolism in patients with concomitant thrombocytopenia: a survey of Canadian practitioners. Blood. 2014;124(21):2174. doi:10.1182/blood.V124.21.2174.2174
    1. Leader A, Ten Cate V, Ten Cate-Hoek AJ, et al. Anticoagulation in thrombocytopenic patients with hematological malignancy: a multinational clinical vignette-based experiment. Eur J Intern Med. 2020;77:86-96. doi:10.1016/j.ejim.2020.03.005
    1. Carney BJ, Wang TF, Ren S, et al. Anticoagulation in cancer-associated thromboembolism with thrombocytopenia: a prospective, multi-center cohort study. Blood Adv. 2021;5(24):5546-5553. doi:10.1182/bloodadvances.2021005966
    1. Samuelson Bannow BR, Lee AYY, Khorana AA, et al. Management of anticoagulation for cancer-associated thrombosis in patients with thrombocytopenia: a systematic review. Res Pract Thromb Haemost. 2018;2(4):664-669. doi:10.1002/rth2.12111
    1. Houghton DE, Key NS, Zakai NA, Laux JP, Shea TC, Moll S. Analysis of anticoagulation strategies for venous thromboembolism during severe thrombocytopenia in patients with hematologic malignancies: a retrospective cohort. Leuk Lymphoma. 2017;58(11):2573-2581. doi:10.1080/10428194.2017.1306644

Publication types

MeSH terms